Robert Peter Gale
ORCID: 0000-0002-9156-1676
· 1 paper in corpus
Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm-associated (MPN) myelofibrosis. However, often there are dose reductions and/or therapy interruptions because of therapy-related adverse events (AEs), especially ane…